In March 2020, rules that had governed American medicine for decades loosened almost overnight. Medicare began paying for video visits in patients' homes. States waived licensing requirements. Federal regulators allowed controlled substances to be prescribed without an in-person exam. Within weeks, telehealth went from a niche service to a primary point of care for millions of people.

The experiment answered a question policymakers had debated for years: could remote care work at scale? In many cases, it could. Yet when the emergency ended, much of that flexibility did not become permanent. It was extended in short increments, renegotiated, narrowed, or allowed to lapse, leaving patients and providers uncertain about what would still be allowed.

This raises a puzzle. If the technology works and patients value it, why does telehealth still face such resistance? The answer lies less in technology than in three policy structures built for a world of physical clinics: state licensure, payment rules, and fraud controls. Each reflects a legitimate concern. Each also shapes who gets care, and where.

American medical licensing is a state function. A physician licensed in Ohio may treat patients in Ohio, and in most cases the legally relevant location is where the patient sits, not where the clinician works. A video visit with a patient across the Indiana border is, in legal terms, the practice of medicine in Indiana. Without an Indiana license, it may be unauthorized.

This arrangement predates the telephone. States regulate medicine under their police powers, and licensing boards are the mechanism for accountability: they verify training, investigate complaints, and revoke licenses. Defenders argue that local boards protect patients by keeping oversight close to where harm occurs. Critics respond that medical education, examinations, and board certification are already national, so fifty separate gatekeepers add cost and delay without adding much safety.

The practical effect falls hardest on continuity of care. A college student who studies out of state, a patient who travels to a distant cancer center and returns home, or a rural resident whose nearest specialist practices across a state line may find that their clinician cannot legally see them by video. Workarounds exist. The Interstate Medical Licensure Compact streamlines applications for physicians, and parallel compacts cover nurses and psychologists. But most compacts expedite multiple licenses rather than replace them, so fees, paperwork, and renewal cycles still multiply.

There is a revealing counterexample. The Department of Veterans Affairs allows its clinicians to treat veterans across state lines under a single state license, a federal arrangement that has operated for years without evident harm to patients. Its existence suggests the barrier is less about clinical safety than about institutional design, and about who holds regulatory authority. Licensure reform is therefore as much a question of federalism and professional self-governance as of patient protection.

Takeaway

When a rule ties care to a patient's physical location, it is worth asking whether geography is protecting patients or simply protecting the jurisdictions that regulate them.

Before 2020, Medicare paid for telehealth only in narrow circumstances. Patients generally had to live in designated rural areas and travel to a clinic or other approved 'originating site' to connect with a distant clinician. Video visits from home were largely excluded. Private insurers and state Medicaid programs varied widely. For most providers, payment rather than technology was the binding constraint on offering remote care.

During the pandemic, Medicare and many states moved toward payment parity, paying the same rate for a virtual visit as for a comparable in-person one. Proponents argue this is essential. The clinician's time, judgment, and liability are the same regardless of modality, and lower rates would push practices away from telehealth just as patients had come to rely on it. Parity, in this view, keeps the choice of format clinical rather than financial.

Skeptics, including many health economists, raise two objections. First, cost structures differ: a virtual visit may not require an exam room, front-desk staff, or equipment, so identical payment could overcompensate. Second, and more consequential, is the question of substitution versus addition. If telehealth replaces in-person visits, total spending stays roughly flat. If it adds visits on top of existing care, because convenience lowers the threshold for seeking help, total spending rises, and payers worry about funding volume that may not improve health.

The evidence remains mixed and context-dependent. Telehealth appears to substitute well for some services, such as behavioral health follow-ups and medication management, and less clearly for others where a physical exam matters. This is why the debate persists. Payment rates are not merely accounting decisions; they signal which kinds of care a system wants more of. Set the rate too low and access shrinks. Set it too high and volume may grow faster than value.

Takeaway

A payment rate is a policy instrument disguised as a price: it quietly decides which care gets delivered, by whom, and how much of it.

Regulators' wariness about telehealth is not purely hypothetical. Federal enforcement actions have uncovered schemes in which companies used brief telephone consultations, or no genuine consultation at all, to generate orders for unnecessary genetic tests, durable medical equipment, and other high-margin items billed to Medicare. Alleged losses across some of these cases ran into the billions of dollars, and they left a lasting impression on oversight agencies.

These cases shape policy because they exploit a structural feature of remote care: it scales easily. A fraudulent clinic once required physical space, staff, and patients walking through the door. A fraudulent telehealth operation can generate thousands of claims from a call center, with recruited clinicians signing orders for patients they never meaningfully assessed. The same frictionlessness that improves access for legitimate patients also lowers the cost of abuse.

Controlled substances illustrate the tension most clearly. The Ryan Haight Act of 2008 generally required an in-person evaluation before a clinician could prescribe controlled substances via telemedicine, a response to rogue online pharmacies distributing opioids. Pandemic waivers suspended that requirement, enabling remote treatment of opioid use disorder and mental health conditions for patients who had struggled to reach care. They also allowed some digital health companies to prescribe stimulants at volumes that drew regulatory scrutiny. Writing rules that preserve the first outcome while preventing the second has proven difficult.

Policy responses tend to follow a familiar pattern: requirements for periodic in-person visits, limits on audio-only services, documentation mandates, and closer auditing of high-volume billers. Each guardrail reduces some risk. Each also adds friction for legitimate patients, often those with the least flexibility, such as rural residents, people with disabilities, or households without reliable broadband. The central design challenge is targeting the behavior rather than the modality.

Takeaway

Rules written in response to the worst actors tend to land on everyone; the more useful question is whether a safeguard targets the fraud itself or merely the format it happened to use.

Telehealth's regulatory barriers share a common origin. Licensure, payment, and fraud controls were all designed around a physical encounter, where location, cost, and verification were anchored to a building and a patient in the room.

The pandemic showed that those assumptions could be relaxed without collapse. It did not show that they could be discarded without consequence. Each barrier protects something real: accountability, fiscal discipline, program integrity. Each also restricts access in ways that fall unevenly across populations.

Victor Fuchs argued that health policy is ultimately about choices among competing goods. Telehealth makes those choices unusually visible. The question is not whether remote care should be regulated, but whether rules built for clinics can be redesigned for care that no longer requires one.